Hybio Pharmaceutical

Developer and manufacturer of polypeptide drugs and APis

placeShenzhen, Guangdong Province, China calendar_todayFounded 1998 groups975 employees language hybio.com.cn

Innovation

173 patent families (22 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing, Emerging technologies; filing pace steady. Cited 1,397 times.

YearFilings
20157
201610
201723
201821
201927
202033
202136
20226
20234
202417
202519
20262

Investor mix

3 investors on record; lead investors include Shenzhen Capital Group.

Investor typeCountShare
Venture capital267%
Private equity133%
Coming soon